% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Guan:141812,
      author       = {Z. Guan$^*$ and H. Yu$^*$ and K. Cuk$^*$ and Y. Zhang$^*$
                      and H. Brenner$^*$},
      title        = {{W}hole-blood {DNA} methylation markers in early detection
                      of breast cancer: a systematic literature review.},
      journal      = {Cancer epidemiology, biomarkers $\&$ prevention},
      volume       = {28},
      number       = {3},
      issn         = {1538-7755},
      address      = {Philadelphia, Pa.},
      publisher    = {AACR},
      reportid     = {DKFZ-2018-02080},
      pages        = {496-505},
      year         = {2019},
      abstract     = {Whole-blood DNA methylation markers have been suggested as
                      potential biomarkers for early detection of breast cancer
                      (BC). We conducted a systematic review of literature on
                      whole-blood DNA methylation markers for BC detection. PubMed
                      and ISI Web of Knowledge were searched up to 29th May 2018.
                      Overall, 33 studies evaluating 355 markers were included.
                      The diagnostic value of most individual markers was
                      relatively modest, with only 6 markers showing sensitivity
                      $>40\%$ at specificity $>75\%$ (only 2 (HYAL2 and S100P)
                      were independently validated). Although relatively strong
                      associations (OR<=0.5 or OR>=2) with BC were reported for 14
                      markers, most of them were not independently validated. Two
                      prospective studies performed epigenome-wide association
                      analysis and identified 276 CpG sites related to BC risk,
                      but no overlap was observed between CpGs reported from these
                      2 studies. Five studies incorporated individual markers as
                      panels but only 2 of them used a test-validation approach.
                      In conclusion, so far detected methylation markers are
                      insufficient for BC early detection, but markers or
                      marker-combinations may be useful for BC risk
                      stratification. Utilizing high-throughput methods of
                      methylation quantification, future studies should focus on
                      further mining informative methylation markers and
                      derivation of enhanced multi-maker panels with thorough
                      external validation ideally in prospective settings.},
      subtyp        = {Review Article},
      cin          = {C070 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30487132},
      doi          = {10.1158/1055-9965.EPI-18-0378},
      url          = {https://inrepo02.dkfz.de/record/141812},
}